multiple%20myeloma
MULTIPLE MYELOMA

Multiple myeloma is a bone marrow disease characterized by the presence of malignant plasma cells, & abnormal serum &/or urine immunoglobulin secondary to clonal plasma cell expansion.

It accounts for 1-2% of all cancers worldwide & mostly affects patients at ages 65-74 years old.

Patient usually presents with bone pain & nonspecific symptoms, or due to abnormalities in laboratory exams.

 

Drug Information

Indication: Metastatic breast cancer. Advanced ovarian cancer in women who have failed a 1st-line platinum-based chemother...

Darzalex
daratumumab

Indication: In combination w/ bortezomib, melphalan, prednisone for patients w/ newly diagnosed multiple myeloma ineligibl...

Indication: Anemia associated w/ chronic renal failure in adults & paed on dialysis. Anemia & reduction of transfu...

Indication: Agammaglobulinemia/hypogammaglobulinemia. Combined therapy w/ antibiotics in severe bacterial or viral infecti...

Indication: Monotherapy in patients w/ chronic lymphocytic leukaemia; indolent B-cell non-Hodgkin's lymphomas that has pro...

Indication: Multiple myeloma. Mantle cell lymphoma in patients who have received at least 1 prior therapy.

Indication: Multiple myeloma & mantle cell lymphoma (MCL) in patients who have received at least 1 prior therapy.

Indication: Regression in neoplastic conditions eg, acute leukaemia, Wilms' tumour, neuroblastoma, soft tissue & bone ...

Indication: Tab: Multiple myeloma, advanced ovarian adenocarcinoma, breast carcinoma, polycythaemia rubra vera. Inj: Local...

Indication: Replacement therapy for acute adrenocortical insufficiency eg, Addison's disease, bilateral adrenalectomy; rel...

1  /  5
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Jay Zhu, Dr. Lai Fung Li, Prof. Chae-Yong Kim, 27 Nov 2019
The current standard of care for glioblastoma multiforme (GBM), an aggressive primary brain tumour with a rapid disease course, consists of maximum safe surgical resection followed by radiotherapy with concomitant temozolomide (TMZ) chemotherapy and subsequent TMZ maintenance. At the 16th Annual Meeting of the Asian Society of Neuro-Oncology (ASNO) in Taipei, Taiwan, experts reviewed the evidence and shared their clinical experience on the use of tumour treating fields (TTFields), a novel treatment modality for GBM.